Drug intelligence / Profile preview

Streptococcus pneumoniae type 6B capsular polysaccharide diphtheria CRM197 protein conjugate antigen

Development stage
Approved
Lead developer
Pfizer
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular
01

Overview

Streptococcus pneumoniae type 6B capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a component of pneumococcal conjugate vaccines. It consists of the purified capsular polysaccharide from Streptococcus pneumoniae serotype 6B chemically linked (conjugated) to CRM197, a non-toxic mutant of diphtheria toxin used as a carrier protein to enhance immunogenicity[2][3][7]. This conjugation enables the immune system to mount a robust T-cell dependent response against the bacterial capsule. The primary indication is active immunization for the prevention of invasive diseases caused by Streptococcus pneumoniae, such as pneumococcal pneumonia and bacteremia[2][3]. The mechanism involves inducing production of antibodies that target the serotype-specific capsule, facilitating opsonization and clearance of the bacteria. Vaccines containing this antigen are developed for pediatric and adult use.

Brand names
PrevnarPrevnar 13Prevnar13Prevnar-13Prevnar 20Prevnar20Prevnar-20
Other names
pneumococcal capsular polysaccharide type 6B vaccinepneumococcal polysaccharide serotype 6B
02

Targets

BCR-Sp6B (Human B-cell receptor specific for Streptococcus pneumoniae type 6B capsular polysaccharide)TCR-CRM197 (CRM197-specific T-cell receptor)6B CPS (Streptococcus pneumoniae serotype 6B capsular polysaccharide)

Beyond the preview

Go deeper on Streptococcus pneumoniae type 6B capsular polysaccharide diphtheria CRM197 protein conjugate antigen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Streptococcus pneumoniae type 6B capsular polysaccharide diphtheria CRM197 protein conjugate antigen.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call